Proton Pump Inhibitors May Increase Fracture Risk
Use of histamine 2 receptor antagonists not significantly associated with fracture risk
WEDNESDAY, May 11 (HealthDay News) -- Use of proton pump inhibitors (PPIs), but not histamine 2 receptor antagonists (H2RAs), is associated with an increased risk of fracture, according to a meta-analysis published in the May/June issue of the Annals of Family Medicine.
Chun-Sick Eom, M.D., M.P.H., from the Seoul National University College of Medicine in South Korea, and colleagues analyzed literature published through 2010 to evaluate the association between the use of PPIs and H2RAs and fracture risk. Five case-control studies, three nested case-control studies, and three cohort studies were included in the meta-analysis.
The investigators found that, compared to nonuse of the respective medications, overall use of PPIs was correlated with a significantly increased risk of any fracture (pooled odds ratio (OR), 1.29), whereas use of H2RAs was not correlated with an increased fracture risk. Long-term H2RA use was not significantly associated with fracture risk but long-term use of PPIs increased the risk of any fracture (adjusted OR, 1.30) and hip fracture (adjusted OR, 1.34).
"In this meta-analysis of observational studies, we found that the use of PPIs was associated with a moderate increase in the risk of fracture compared with nonuse of PPIs, whereas we did not observe any significant association between H2RA use and this risk," the authors write.